Pharmanovia

Executive Summary

Pharmanovia is a UK-based global specialty pharmaceutical company founded in 2013 that focuses on acquiring, licensing, and commercializing established off-patent medicines through life cycle management strategies. Operating across more than 160 markets, the company's portfolio spans cardiovascular, endocrinology, neurology, and oncology. By revitalizing mature drugs—improving formulations, expanding indications, or enhancing delivery—Pharmanovia creates value while improving patient outcomes. The company's asset-light model, combined with deep regulatory expertise and a broad commercial network, positions it well to capture growth in the generic and specialty generics space. With a proven track record of over a decade, Pharmanovia continues to expand its pipeline and geographic footprint, offering a resilient business model less dependent on early-stage R&D risks.

Upcoming Catalysts (preview)

• Q3 2026New product acquisition or in-licensing deal70% success
• Q1 2027Regulatory approval for a lifecycle extension (e.g., new indication or formulation)60% success
• Q4 2026Expansion into a new major market (e.g., China or Japan)65% success